Search results
Results from the WOW.Com Content Network
Dupilumab is injected under the skin, usually once every 2 to 4 weeks. Your first dose may be given in 2 injections. Take a syringe or pen out of the refrigerator and let it reach room temperature for 30 to 45 minutes before injecting your dose. Leave the needle cap on until you are ready to inject your dose.
Applies to dupilumab: subcutaneous solution. Serious side effects of dupilumab. Along with its needed effects, dupilumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor immediately if any of the following side effects occur while taking ...
Dupixent (dupilumab) may be used to treat moderate-to-severe eczema, moderate-to-severe eosinophilic or oral-corticosteroid-dependent asthma, chronic rhinosinusitis with nasal polyps, COPD with an eosinophilic phenotype, eosinophilic esophagitis, or pruri
6 to 17 years: Weight 15 to less than 30 kg: Initial loading dose: 600 mg subcutaneously once. Subsequent doses: 300 mg subcutaneously every 4 weeks. Weight 30 to less than 60 kg: Initial loading dose: 400 mg subcutaneously once. Subsequent doses: 200 mg subcutaneously every other week.
May 20, 2022. Approval FDA Approves Dupixent (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis. Oct 20, 2021. Approval FDA Expands Approval of Dupixent (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma. Jun 19, 2020.
Dupixent (generic name: dupilumab) is approved to treat certain age groups with eczema (atopic dermatitis), asthma, chronic rhinosinusitis (sinus and nasal cavity swelling) with nasal polyps (tissue growths), chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis, and prurigo nodularis (a skin condition). Dupixent works blocking ...
Dupilumab did not alter immune response to tetanus antigen; immune responses to diphtheria and pertussis antigens not assessed. Vaccines, live. Not known if administration of live vaccines during dupilumab treatment will impact safety or effectiveness of these vaccines. Do not use in patients receiving dupilumab. Warfarin
Dupilumab (Ingredient) Drugbank ID: DB12159. The information below refers to products available in the United States that contain dupilumab. Products containing dupilumab dupilumab systemic. Brand name: Dupixent Drug class: interleukin inhibitors. Dupilumab systemic is used in the treatment of: Asthma; Asthma, Maintenance; Atopic Dermatitis
Dupilumab Interactions There are 88 drugs known to interact with dupilumab , along with 3 disease interactions. Of the total drug interactions, 42 are major, 38 are moderate, and 8 are minor.
No, Dupixent (dupilumab) is not an immunosuppressant or a steroid. Dupixent works by targeting a type of protein called an interleukin, that is involved in inflammation. Dupixent calms an overreactive immune system but does not suppress the immune system. This leads to fewer and less severe episodes of inflammation when used to treat conditions ...